Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | NQO2 | P16083 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | FABP4 | P15090 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | GPR3 | P46089 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9654009 | 0.74 | IDO1 (0.42) | MEN1KMT2AKDM4EGPR3ALDH1A1 | |
| SCHEMBL29473770 | 0.74 | GPR84 (0.57) | KMT2AKDM4ENQO2GPR3ALDH1A1 | |
| SCHEMBL146530 | 0.74 | GPR84 (0.57) | KMT2AKDM4ENQO2GPR3ALDH1A1 | |
| SCHEMBL3841620 | 0.74 | HTR6 (0.46) | MEN1KMT2ASLC6A2KDM4ENQO2 | |
| SCHEMBL11954801 | 0.74 | SLC6A2 (0.41) | MEN1KMT2ASLC6A2KDM4ENQO2 | |
| SCHEMBL8927740 | 0.73 | GPR3 (0.36) | MEN1KMT2AKDM4EGPR3ALDH1A1 | |
| SCHEMBL6114157 | 0.73 | SLC6A2 (0.43) | MEN1KMT2ASLC6A2KDM4ENQO2 | |
| SCHEMBL14141407 | 0.73 | SLC6A2 (0.43) | MEN1KMT2ASLC6A2KDM4ENQO2 | |
| SCHEMBL18509203 | 0.73 | SLC6A2 (0.43) | MEN1KMT2ASLC6A2KDM4ENQO2 | |
| SCHEMBL2790587 | 0.73 | SLC6A2 (0.43) | MEN1KMT2ASLC6A2KDM4ENQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117946045-A | Nannochloride alcohol derivative | 山东第一医科大学(山东省医学科学院) | 2024-04-30 | — | — | CN | disclosed |
| EP-3399968-B1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LTD (KY) | 2021-10-20 | — | — | EP | disclosed |
| WO-2021045207-A1 | MECHANOREDOX REACTION USING PIEZOELECTRIC MATERIAL, AND PRODUCTION METHOD USING SAID REACTION | 国立大学法人北海道大学 | 2021-03-11 | — | — | WO | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
| CN-105392787-B | For treating and preventing the azepine oxindole of respiratory syncytial virus infection | 豪夫迈·罗氏有限公司 | 2017-11-24 | — | — | CN | disclosed |
| CN-105392787-A | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN LA ROCHE | 2016-03-09 | — | — | CN | disclosed |
| EP-2230242-A1 | Synthesis of new asymmetrically meso-substituted water-soluble porphyrins acting as cytostatic agents | Johannes Kepler Universität (AT) | 2010-09-22 | — | — | EP | disclosed |
| CN-101410531-A | Genetic markers for skatole metabolism | UNIV GUELPH (CA) | 2009-04-15 | — | — | CN | disclosed |
| US-5614498-A | OLIGOPEPTIDES, BRONCHDILATORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1997-03-25 | — | — | US | disclosed |
| US-5496928-A | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0555537-A2 | Endothelin antagonistic substance | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1993-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | MEN1 3422/4885KMT2A 2411/4885SLC6A2 2783/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | MEN1 3422/4885KMT2A 2411/4885SLC6A2 2783/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.